EX-2.1
from 10-K
83 pages
Portions of This Exhibit (Indicated by “[**]”) Have Been Omitted Pursuant to Item 601(b)(2)(ii) of Regulation S-K. Schedules and Similar Attachments to This Exhibit Have Been Omitted Pursuant to Item 601(a)(5) of Regulation S-K. Purchase and Sale Agreement by and Among Alkermes Pharma Ireland Limited, Daravita Limited, Eagle Holdings USA, Inc., Recro Pharma, Inc. and Recro Pharma LLC Dated as of March 7, 2015
12/34/56
EX-2.1
from 8-K
96 pages
In Accordance With Item 601(b)(2)(ii) of Regulation S-K, Certain Information (Indicated by “[**]”) Has Been Excluded From This Exhibit Because It Is Both Not Material and Would Likely Cause Competitive Harm to the Registrant if Publicly Disclosed. Agreement and Plan of Merger by and Among Alkermes, Inc., Thinker Merger Sub, Inc., Alkermes plc, Rodin Therapeutics, Inc. and Shareholder Representative Services LLC, as Company Equityholder Representative Dated as of November 14, 2019
12/34/56
EX-2.1
from 8-K/A
133 pages
Purchase and Sale Agreement by and Among Alkermes Pharma Ireland Limited, Daravita Limited, Eagle Holdings USA, Inc., Recro Pharma, Inc. and Recro Pharma LLC Dated as of March 7, 2015
12/34/56
